Home » DSM Receives Outsourcing Award for Carbon Footprint Reduction
DSM Receives Outsourcing Award for Carbon Footprint Reduction
PharmaManufacturing.com
10/07/2010
DSM applied its InnoSyn route scouting services to launch a collaborative research program to identify a faster route for a drug intermediate using (bio)catalytic processes with the same level of reliability and quality, yet with a reduced carbon footprint of over fifty percent. The new process resulted also in shorter cycle times due to fewer steps in the process.
André de Vries, Ph.D., Competence Manager for Homogeneous Catalysis at DSM, commented, “This project involved scientists covering all relevant areas of organic process development, including biocatalysis and homogeneous catalysis. From the 10 new identified routes, all less than 5 steps, the route combining a biocatalytic and a metal-catalyzed step showed to be most sustainable. In this way, DSM as the contract manufacturer is contributing to extending the life cycle of the customer’s product using innovation to decrease the eco footprint.”
Dr Kevin Robinson, Editorial Director, Pharma magazine and judging coordinator, stated: "The European Outsourcing Awards judging panel is selected to give an impartial, professional and wide-ranging level of expertise and is assembled exclusively from leading healthcare organisations and top business school academics.” DSM was nominated under the categories of Most Improved Process, Plant or Facility, which focuses on expertise and innovation to meet customer requirements for time-to-market, and Best Contract Manufacturing Project, which focuses on production and commercial manufacturing innovation, cost-effectiveness and regulatory compliance.
Organized by Via Media UK Ltd in conjunction with Via Connect, a provider of various forums and events to the bio/pharmaceutical, nutraceutical and personal care industries, the European Outsourcing Awards gala dinner was held in Paris, France, during the week of the CPhI Worldwide trade event.
More News:
-
06/18/2013
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
-
06/18/2013
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
-
06/18/2013
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
-
06/18/2013
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
-
06/17/2013
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
-
06/14/2013
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
-
06/14/2013
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
-
06/13/2013
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
-
06/13/2013
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
-
06/13/2013
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »
Get Connected Now!
- Featured White Papers

Print page